The purpose of this study is to learn whether female patients undergoing a heart catheterization procedure to open a blood vessel(s) experience more success when the procedure is performed through the leg or through the arm. The study is also trying to determine if there is a lower complication rate when this procedure is performed through the leg or through the arm. The study will include 3000 people in the United States.
Subjects that have previously had a heart attack may be at an increased risk of sudden cardiac death (life-threatening heart rhythm disturbances). This study is looking to identify a series of lab tests that will specifically predict the risk of arrhythmic death in order to work to preventing in the future.
We are seeking volunteers who have had a heart attack one to three years ago (2008 through 2010).
The drug being studied is ticagrelor, a platelet inhibitor.
The purpose of this study is to determine if the study medication will reduce the chances of another heart attack or stroke.
To qualify for the study you must be at least 50 years old, have had a prior heart attack (see above) and meet certain other criteria.
All lab work, EKG's, physical exams, etc. are provided at no cost.
Compensation is available for travel and expenses.
For patients requiring a cardiac catheterization using a FDA approved catheter (Liposcan/IVUS) that collects data during the procedure. Patients will recieve follow up phone calls at 30 days, 6 months, 1 year and 2 year intervals.
This is a phase 4 trial that is investigating the diabetes drug already approved by the FDA (Onglyza or saxagliptin). The purpose of this study is to see if adding Onglyza to the other medications you are already taking will reduce your risk of cardiovascular disease. You must be over 40 years old and have type II diabetes to be in this study. You will be required to come in for study visits every 6 months. All study visits including lab tests and EKG's are free of charge.